Liver cirrhosis
Conditions
Interventions
Zinc preparation low dose group 25 mg twice daily
Zinc formulation high dose group 50 mg twice daily, after 4 weeks maximum dose 50 mg three times a day
Sponsors
Hyogo college of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with histologically or radiologically confirmed liver cirrhosis with sarcopenia. 2.Patients with zinc deficiency related clinical symptom. 3.Patients with hypozincemia. 4.Patients with Child-Pugh score 10 or less. 5.Liver cirrhosis patients in whom ADL is maintained for more than one year and who are expected to consume a certain dietary amount. 6. Previous antiviral therapies or nutritional therapies for liver cirrhosis are not limited. 7. Patients with written informed consent by their free will after the full explanation of this study.
Exclusion criteria
Exclusion criteria: 1.Patients with Child-Pugh score 11 or more. 2.Patients with severe underlying diseases. 3.Patients who were judged to be inappropriate for this study by attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of sarcopenia after 48 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle mass and muscle strength Energy metabolism Protein metabolism Baseline data Visceral fat area | — |
Countries
Japan
Contacts
Public ContactKazunori Yoh
Hyogo college of medicine Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine
Outcome results
None listed